Skip to main content
REYON PHARMACEUTICAL CO., LTD logo

REYON PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 102460 ISIN · KR7102460003 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-02-26 Major Shareholding Noti…
Country KR South Korea
Listing KO 102460

About REYON PHARMACEUTICAL CO., LTD

https://www.reyonpharm.co.kr/

REYON PHARMACEUTICAL CO., LTD. is a research-driven company engaged in the development and manufacturing of chemical and biopharmaceutical products. Its primary business areas encompass the production of Active Pharmaceutical Ingredients (APIs), a diverse portfolio of generic medicines, and contrast agents. The company leverages advanced synthesis know-how to supply high-value APIs to domestic and international partners. A key strategic focus is the development of next-generation biopharmaceuticals, including gene therapies for conditions like wet age-related macular degeneration and NK cell therapies for solid cancers. Reyon is also expanding its capabilities to offer contract development and manufacturing (CDMO) services for complex biologic drugs.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders (insiders) and their special relations, including specific transaction dates, methods (e.g., off-market trading), and updated shareholding percentages. This falls under the category of Major Shareholding Notification.
2025-02-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the change in share ownership by a director (Soon-Ok Jeong) of Reyon Pharmaceutical. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider transactions and changes in holdings by company leadership.
2025-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Lee-Won Pharm) announcing a significant change in sales or profit structure (30% or more). This is a standard preliminary earnings announcement (often referred to as '잠정실적' in Korea) that provides key financial highlights before the final audited annual report is released. It fits the definition of an Earnings Release (ER) as it provides initial financial highlights for the period. FY 2024
2025-02-13 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 1% confidence The document is an official regulatory filing from a Korean company (Lee-on Pharmaceutical) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate as it covers updates on financing activities and capital structure changes, including adjustments to convertible securities.
2025-01-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of major shareholders and their special relations. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-01-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of major shareholders and their special relations. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-12-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.